Fresh Equities
ASX:ANP

ASX:ANP

ANTISENSE THERAPEUTICS LIMITED

4W AVG VOLUME
758.7k
Data provided by Weblink | as of close 2020-01-24
4W AVG TURNOVER
$61.48k

ANTISENSE THERAPEUTICS LIMITED has not announced any current capital raises, but we are collecting interest for future raises.

Demand Registered for Next Raise
< $50k
Investors Interested in Next Raise
< 10
How Fresh Equities Works
Authentication

1. Create Account

Complete your onboarding digitally in less than 3 minutes.

Authentication

2. View Terms

View the full term sheet for the capital raise.

Authentication

3. Bid for Allocation

Submit and track your bid online.

Capital Raise History

10 March 2019

Placement
Raised
$1.6m
Offer Price
$0.033
Discount
-
Price at Close
-
Market Cap
-
Re-listed
12-03-2019

Company Overview

Antisense Therapeutics Limited (ANP.ASX) is an Australian publicly traded biopharmaceutical drug discovery and development company whose mission is to create, develop and commercialize novel antisense therapeutics for a variety of drug candidates including Duchenne Muscular Dystrophy (DMD), Multiple Sclerosis (MS), and Acromegaly.

Type

Listed Company

GICS Sub-industry

Pharmaceuticals

Head Office

6 Wallace Ave, Toorak VIC 3142, Australia

Pharmaceuticals
Health Care
Biotech
Biotech & Health

Price Chart


Quarterly Cash Flows

The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.

Loading...


Directors

Fresh Equities does not have ANTISENSE THERAPEUTICS LIMITED directors data.


Announcements

All
All Time
    ANP Presentation for SACHS 3rd Neuroscience Innovation Forum on 12 January 2020

    Periodic Reports

    ANP to Present at Neuroscience Innovation Forum in the US on 9 January 2020

    Other

  • Antisense Therapeutics Limited - Listed Options raise $5.5M on 3 January 2020

    Issued Capital

  • Appendix 3B and 708A notice on 3 January 2020

    Issued Capital

    Change of Director's Interest Notice (RM, MD, GM, GP, WG) on 23 December 2019

    Shareholder Details

    Appendix 3B on 23 December 2019

    Issued Capital

    Change in substantial holding on 23 December 2019

    Shareholder Details

    Change in substantial holding from AEF on 20 December 2019

    Shareholder Details

    Change of Director's Interest Notice - WG on 19 December 2019

    Shareholder Details

    Change of Director's Interest Notice - RM on 19 December 2019

    Shareholder Details

    Load More

News

Fresh Equities does not have ANTISENSE THERAPEUTICS LIMITED news data.